Showing results (311-320 of 365) with videos related to

Sort By:
Pageof 37
Neuro-Oncology|April 19, 2013
Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collectiveBenedikt Wiestler, Rainer Claus, Sabine A Hartlieb, et al.
Cell Stem Cell|August 28, 2014
Identification of regulatory networks in HSCs and their immediate progeny via integrated proteome, transcriptome, and DNA methylome analysisNina Cabezas-Wallscheid, Daniel Klimmeck, Jenny Hansson, et al.
Cancer Discovery|August 30, 2012
Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylationStefan T Börno, Axel Fischer, Martin Kerick, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 12, 2009
Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemiaShih-Shih Chen, Aparna Raval, Amy J Johnson, et al.
Nature Communications|September 24, 2017
Mitochondrial mutations drive prostate cancer aggressionJulia F Hopkins, Veronica Y Sabelnykova, Joachim Weischenfeldt, et al.
Clinical Sarcoma Research|May 10, 2017
Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated casesChristian Koelsche, Daniel Schrimpf, Lars Tharun, et al.
Nature Genetics|January 19, 2016
DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemiaChristopher C Oakes, Marc Seifert, Yassen Assenov, et al.
Science Advances|September 7, 2022
Pronounced sequence specificity of the TET enzyme catalytic domain guides its cellular functionMirunalini Ravichandran, Dominik Rafalski, Claudia I Davies, et al.
International Journal of Cancer|March 28, 2018
A PRDX1-p38α heterodimer amplifies MET-driven invasion of IDH-wildtype and IDH-mutant gliomasPeter Wirthschaft, Julia Bode, Anika E M Simon, et al.
Leukemia & Lymphoma|February 28, 2015
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997David M Lucas, Amy S Ruppert, Gerard Lozanski, et al.
Pageof 37